Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

285 results about "Microbial Genes" patented technology

Nucleic acid composition for detecting novel coronavirus COVID-19 and application

The invention discloses a nucleic acid composition for detecting novel coronavirus COVID-19 and application. The nucleic acid composition is prepared by the following steps: firstly, carrying out nucleic acid sample amplification based on a transcription-mediated amplification technology (TMA); then, specifically detecting amplified virus target nucleic acid in combination with activity of 'associated cleavage' of CRISPR-Cas13a protease; adding sgRNA, Cas13a protein, an ssRNA signal report probe and a reaction buffer solution into a reaction system containing target nucleic acid to be detected; and reading and detecting signals when the reaction is carried out so as to detect a target gene. By using the method disclosed by the invention, whether a sample contains a target nucleic acid sequence or not can be rapidly detected; and the nucleic acid composition is combined with the transcription-mediated nucleic acid amplification technology, so that the sensitivity of the detection methodcan reach a nanomole level, and the nucleic acid composition for detecting the novel coronavirus COVID-19 is suitable for rapidly detecting pathogenic microorganisms, gene mutation, specific target RNA and the like.
Owner:NOVOPROTEIN SCI INC

Bacillus licheniformis engineering bacteria for nattokinase production and method for producing nattokinase by using bacillus licheniformis engineering bacteria

ActiveCN104630124AAchieve secretory expressionSecreted expression highly mediatedBacteriaMicroorganism based processesBacillus licheniformisShuttle vector
Disclosed are bacillus licheniformis engineering bacteria for nattokinase production and a method for producing nattokinase by using the bacillus licheniformis engineering bacteria, which belong to the technical fields of microorganism genetic engineering and enzyme engineering. According to the invention, a nattokinase gene of bacillus subtilis MBS04-6 is obtained through PCR technology augmentation. Bacillus licheniformis BL10 is utilized as an expression host; promoter P43 of bacillus subtilis 168 is taken as a promoter; a signal peptide of extracellular serine protease Vpr of bacillus licheniformis WX-02 is taken a signal peptide; and a terminator sequence of alpha-amylase of bacillus licheniformis WX-02 is taken as a terminator. The expression elements are connected to shuttle vector pHY300PLK to form an expression vector, and the expression vector is transformed into the bacillus licheniformis BL10 to obtain the bacillus licheniformis engineering bacteria BL10 (pP43SNT) for nattokinase production. The bacterial strain has been deposited with the China Center for Type Culture Collection (CCTCC) at September 10th, 2013, and the accession number is CCTCC NO:M2013401. The invention also provides a method of the bacterial strain for producing nattokinase, and the maximum enzyme activity can reach 11.37 FU/mL in a liquid fermentation medium.
Owner:HUAZHONG AGRI UNIV

Respiratory tract micro-fluidic chip rapid detection technology and kit

The invention is based on a micro-fluidic chip technology and performs rapid detection on seven respiratory tract pathogenic bacteria in combination with a nucleic acid isothermal amplification technology, and belongs to the field of safe and rapid detection of respiratory tract pathogenic bacteria. According to the technology, a sample subjected to rapid treatment is mixed with a reagent in a kit. The mixed liquid is added into a micro-fluidic chip. A primer pre-loaded into the micro-fluidic chip is subjected to a nucleic acid isothermal amplification reaction with a possible microbial gene template in the mixed liquid at certain single temperature. A fluorescent dye in the reaction system is combined with an amplification product to generate a fluorescent signal. Whether the seven pathogens exist in the respiratory tract or not is determined through instrument reading. According to the method, the need for the sample quantity is reduced through the micro-fluidic chip technology, the detection throughput is increased, and seven pathogenic bacteria can be detected at the same time. By adopting the nucleic acid isothermal amplification technology, the detection specificity and sensitivity are improved; the operation is simple, and the reaction time is short. A simple and rapid respiratory tract pathogenic bacteria detection technology is provided for clinical use.
Owner:BEIJING BAIKANGXIN BIOLOGICAL SCI & TECH

Strain producing dynamic controlling recombinant strain and method for preparing D-lactic acid with recombinant strain

A Strain producing dynamic controlling recombinant strain and a method for preparing D-lactic acid with the recombinant strain belong to the technical field of genetically engineered agricultural microorganisms. The recombinant strain is named (Escherichia coli)B0013-070B, and is preserved in the China center for type culture collection, and the preservation number is CCTCCNO:M2012071. A lactate dehydrogenase gene promoter ldhAp in the genome of the strain is replaced with a culture environment/nutritional factors control-type promoter. Through the utilization of the recombinant strain, fermentation is conducted for 28 to 40 hours in stages at 25 to 50 DEG C, and the level of producing D-lactic acid reaches 12.5%; the optical purity lives up to 99.9%; and the chemical purity reaches to 98.4%. The dynamic controlling to the D-lactic acid dehydrogenase encoding gene expression on D-lactic acid high-producing strain B0013-070 chromosomes is conducted, so that the gene expression is controlled only through changing the fermentation temperature during the D-lactic acid production process to achieve the purpose of efficiently synthesizing D-lactic acid through taking glucose as a raw material. After simple modification, the invention can be used for producing important microbial metabolites in other industries.
Owner:SHANDONG BAISHENG BIOTECH

LAMP-based (loop-mediated isothermal amplification-based) visual fluorogenic and chromogenic genetic testing method for microorganisms

InactiveCN102586438AMeet the requirements for rapid detection of pathogenic microorganismsThe detection process is fastMicrobiological testing/measurementFluorescence/phosphorescenceMicroorganismFluorescence
The invention discloses an LAMP-based visual fluorogenic and chromogenic genetic testing method for microorganisms, which relates to a genetic testing method for microorganisms. The testing method includes the following steps: (1) buffered peptone water (BPW) is used for culturing a sample to be tested according to a national standard method for 4 hours; (2) a water boiling method is used for extracting DNA (deoxyribonucleic acid) from the sample to be tested; (3) the DNA is added into an LAMP reaction system, and the temperature of 65 DEG C is kept for 1 hour; (4) by means of comparison with a control group, the result of the sample to be tested is observed with naked eyes, and qualitative analysis is carried out on the sample. Compared with the conventional culture method, the genetic testing method has the advantages that: testing is rapid, only taking 5 hours, and plus the extraction of the sample DNA, testing takes less than 6 hours in total; the specificity is good, and the sensitivity is high; the steps are simple, and the repeatability is high; and a plurality of samples can be tested at the same time. The genetic testing method can qualitatively test microorganisms, and can take the place of the conventional culture method and the serological testing method which are used up to now.
Owner:WUHAN UNIV

Biomarker used for early diagnoses of liver cancer and application thereof

The invention relates to a marker for intestinal microecology and application thereof, in particular to a biomarker used for early diagnoses of liver cancer. The biomarker used for early diagnoses ofliver cancer is composed of 34 kinds of genes shown as SEQ ID NO:1-34, and the genes are enriched in intestinal tracts. The invention also provides a detection reagent, and the reagent includes a primer used for detecting the 34 kinds of genes shown as SEQ ID NO:1-34. Feces of patients in groups are collected through a noninvasive method, and 16S rRNA Miseq sequencing of intestinal florae is conducted. During a discovery period of the biomarker, through a random forest law, microorganism gene markers with specificity of early liver cancer are identified among patients suffering from early cirrhosis and liver cancer, patients suffering from cirrhosis and healthy comparisons, an index of a probability of disease (POD) of liver cancer is created, and verification of the markers during the discovery period is achieved. During the verification period of the markers, the POD index of the patients during the verification period is calculated, and verification of the diagnosis value of the patients suffering from liver cancer during the verification period according to the POD index is achieved.
Owner:ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products